New strategy aims to boost surgery success in pancreatic cancer
NCT ID NCT04539808
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The study also tests adding the drug losartan to the chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy drugs (mFOLFIRINOX, gemcitabine/nab-paclitaxel, and losartan)
- What this could lead to
- If successful, this approach could improve the chances of completely removing pancreatic cancer during surgery, potentially extending survival.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to all patients. Chemotherapy side effects can be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?